BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37616542)

  • 1. Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.
    Lemberg KM; Ali ES; Krecmerova M; Aguilar JMH; Alt J; Peters DE; Zhao L; Wu Y; Nuha N; Asara JM; Staedtke V; Pratilas CA; Majer P; Rais R; Ben-Sahra I; Slusher BS
    Mol Cancer Ther; 2023 Dec; 22(12):1390-1403. PubMed ID: 37616542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor.
    Lemberg KM; Zhao L; Wu Y; Veeravalli V; Alt J; Aguilar JMH; Dash RP; Lam J; Tenora L; Rodriguez C; Nedelcovych MT; Brayton C; Majer P; Blakeley JO; Rais R; Slusher BS
    Mol Cancer Ther; 2020 Feb; 19(2):397-408. PubMed ID: 31594823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis.
    González-Muñoz T; Di Giannatale A; García-Silva S; Santos V; Sánchez-Redondo S; Savini C; Graña-Castro O; Blanco-Aparicio C; Fischer S; De Wever O; Creus-Bachiller E; Ortega-Bertran S; Pisapia DJ; Rodríguez-Peralto JL; Fernández-Rodríguez J; Pérez-Portabella CR; Alaggio R; Benassi MS; Pazzaglia L; Scotlandi K; Ratner N; Yohay K; Theuer CP; Peinado H
    Clin Cancer Res; 2023 Sep; 29(18):3744-3758. PubMed ID: 37432984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
    Borcherding DC; Amin NV; He K; Zhang X; Lyu Y; Dehner C; Bhatia H; Gothra A; Daud L; Ruminski P; Pratilas CA; Pollard K; Sundby T; Widemann BC; Hirbe AC
    Clin Cancer Res; 2023 Apr; 29(8):1592-1604. PubMed ID: 36799629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effects of 4-methylumbelliferone, a hyaluronan synthesis inhibitor, on malignant peripheral nerve sheath tumor.
    Ikuta K; Ota T; Zhuo L; Urakawa H; Kozawa E; Hamada S; Kimata K; Ishiguro N; Nishida Y
    Int J Cancer; 2017 Jan; 140(2):469-479. PubMed ID: 27706810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating analysis of proteome profile and drug screening identifies therapeutic potential of MET pathway for the treatment of malignant peripheral nerve sheath tumor.
    Tsuchiya R; Yoshimatsu Y; Noguchi R; Sin Y; Ono T; Akiyama T; Kosako H; Yoshida A; Ohtori S; Kawai A; Kondo T
    Expert Rev Proteomics; 2023; 20(4-6):109-119. PubMed ID: 37229542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors.
    Shih TC; Fan Y; Kiss S; Li X; Deng XN; Liu R; Chen XJ; Carney R; Chen A; Ghosh PM; Lam KS
    Neuro Oncol; 2019 Nov; 21(11):1389-1400. PubMed ID: 31127849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Erb-B2 Receptor Tyrosine Kinase 3 and Associated Regulatory Pathways Potently Impairs Malignant Peripheral Nerve Sheath Tumor Proliferation and Survival.
    Black LE; Longo JF; Anderson JC; Carroll SL
    Am J Pathol; 2023 Sep; 193(9):1298-1318. PubMed ID: 37328102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.
    Fernández-Rodríguez J; Creus-Bachiller E; Zhang X; Martínez-Iniesta M; Ortega-Bertran S; Guha R; Thomas CJ; Wallace MR; Romagosa C; Salazar-Huayna L; Reilly KM; Blakely JO; Serra-Musach J; Pujana MA; Serra E; Villanueva A; Ferrer M; Lázaro C
    Mol Cancer Ther; 2022 Jul; 21(7):1246-1258. PubMed ID: 35511749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors.
    Lopez G; Pollock RE
    Methods Mol Biol; 2017; 1510():365-374. PubMed ID: 27761835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.
    Ghadimi MP; Lopez G; Torres KE; Belousov R; Young ED; Liu J; Brewer KJ; Hoffman A; Lusby K; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2012 Aug; 11(8):1758-69. PubMed ID: 22848094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors.
    Ghadimi MP; Young ED; Belousov R; Zhang Y; Lopez G; Lusby K; Kivlin C; Demicco EG; Creighton CJ; Lazar AJ; Pollock RE; Lev D
    Clin Cancer Res; 2012 May; 18(9):2545-57. PubMed ID: 22407831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth.
    Thomson CS; Pundavela J; Perrino MR; Coover RA; Choi K; Chaney KE; Rizvi TA; Largaespada DA; Ratner N
    Oncogene; 2021 Jun; 40(24):4229-4241. PubMed ID: 34079083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.
    Johansson G; Mahller YY; Collins MH; Kim MO; Nobukuni T; Perentesis J; Cripe TP; Lane HA; Kozma SC; Thomas G; Ratner N
    Mol Cancer Ther; 2008 May; 7(5):1237-45. PubMed ID: 18483311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner.
    Byer SJ; Eckert JM; Brossier NM; Clodfelder-Miller BJ; Turk AN; Carroll AJ; Kappes JC; Zinn KR; Prasain JK; Carroll SL
    Neuro Oncol; 2011 Jan; 13(1):28-41. PubMed ID: 21075781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.
    Larsson AT; Bhatia H; Calizo A; Pollard K; Zhang X; Conniff E; Tibbitts JF; Rono E; Cummins K; Osum SH; Williams KB; Crampton AL; Jubenville T; Schefer D; Yang K; Lyu Y; Pino JC; Bade J; Gross JM; Lisok A; Dehner CA; Chrisinger JSA; He K; Gosline SJC; Pratilas CA; Largaespada DA; Wood DK; Hirbe AC
    Neuro Oncol; 2023 Nov; 25(11):2044-2057. PubMed ID: 37246765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts.
    Butler E; Schwettmann B; Geboers S; Hao G; Kim J; Nham K; Sun X; Laetsch TW; Xu L; Williams NS; Skapek SX
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28639. PubMed ID: 32975370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors.
    Chau V; Lim SK; Mo W; Liu C; Patel AJ; McKay RM; Wei S; Posner BA; De Brabander JK; Williams NS; Parada LF; Le LQ
    Cancer Res; 2014 Jan; 74(2):586-97. PubMed ID: 24285727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
    Ramkissoon A; Chaney KE; Milewski D; Williams KB; Williams RL; Choi K; Miller A; Kalin TV; Pressey JG; Szabo S; Azam M; Largaespada DA; Ratner N
    Clin Cancer Res; 2019 Jul; 25(13):4117-4127. PubMed ID: 30936125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo.
    Schulte A; Ewald F; Spyra M; Smit DJ; Jiang W; Salamon J; Jücker M; Mautner VF
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.